Context. Despite pancreatic cancer (PC) genomic char- acterization, true advances in the development of prog- nosis classification and new therapeutic strategies have yet to come. Objective. We aimed to better understand genomic al- terations of invasive phenotype in order to improve pa- tient selection for treatment options. Methods. We analyzed 37 PC samples by either whole transcriptome or exome sequencing performed at 75- 100 bpx2 on an Illumina platform, matched with normal DNA to identify somatic events. Calls of single nucleo- tide variants and InDels were annotated with 1000 ge- nomes allele frequencies, dbSNP149 rsIDs, Exac and EVS using Oncotator. We detected the pathogenicity of the emerging variants by previous knowledge and bio- informatic mutation-prediction tools. Results. We highlighted 43 recurrently altered genes involving several pathways including chromatine re- modelling and DNA damage repair. The analysis limited on early stage patients (40% of samples) showed how a poor prognosis was significantly associated with a higher number of known PC mutations (pValue=0.047). The subgroup with better overall survival (>25 months) harbors an average of 24 events instead of the one with an overall survival <25 months, that presents an average of 40 mutations. Conclusions. Our data show how a complex genetic profile in early stage could be responsible of more ag- gressiveness, suggesting an urgently need of an innova- tive approach to classify this disease.

Elisa Grassi, S.D. (2017). Higher number of known pancreatic cancer mutations highlighted by whole-transcripto- me and whole-exome sequencing predicts cli- nical outcome in early stage patients. MINERVA GASTROENTEROLOGICA E DIETOLOGICA, 63(Suppl. I N° 4), 21-21.

Higher number of known pancreatic cancer mutations highlighted by whole-transcripto- me and whole-exome sequencing predicts cli- nical outcome in early stage patients

Elisa Grassi
Writing – Original Draft Preparation
;
Sandra Durante
Membro del Collaboration Group
;
Annalisa Astolfi
Formal Analysis
;
Giuseppe Tarantino
Data Curation
;
Valentina Indio
Software
;
Eva Freier
Membro del Collaboration Group
;
Francesca Formica
Membro del Collaboration Group
;
Daria Filippini
Membro del Collaboration Group
;
Claudio Ricci
Membro del Collaboration Group
;
Riccardo Casadei
Membro del Collaboration Group
;
Carla Serra
Membro del Collaboration Group
;
Donatella Santini
Membro del Collaboration Group
;
Antonietta D’Errico
Membro del Collaboration Group
;
Antonio D Pinna
Membro del Collaboration Group
;
Francesco Minni
Membro del Collaboration Group
;
Guido Biasco
Membro del Collaboration Group
;
Mariacristina Di Marco
Project Administration
2017

Abstract

Context. Despite pancreatic cancer (PC) genomic char- acterization, true advances in the development of prog- nosis classification and new therapeutic strategies have yet to come. Objective. We aimed to better understand genomic al- terations of invasive phenotype in order to improve pa- tient selection for treatment options. Methods. We analyzed 37 PC samples by either whole transcriptome or exome sequencing performed at 75- 100 bpx2 on an Illumina platform, matched with normal DNA to identify somatic events. Calls of single nucleo- tide variants and InDels were annotated with 1000 ge- nomes allele frequencies, dbSNP149 rsIDs, Exac and EVS using Oncotator. We detected the pathogenicity of the emerging variants by previous knowledge and bio- informatic mutation-prediction tools. Results. We highlighted 43 recurrently altered genes involving several pathways including chromatine re- modelling and DNA damage repair. The analysis limited on early stage patients (40% of samples) showed how a poor prognosis was significantly associated with a higher number of known PC mutations (pValue=0.047). The subgroup with better overall survival (>25 months) harbors an average of 24 events instead of the one with an overall survival <25 months, that presents an average of 40 mutations. Conclusions. Our data show how a complex genetic profile in early stage could be responsible of more ag- gressiveness, suggesting an urgently need of an innova- tive approach to classify this disease.
2017
Elisa Grassi, S.D. (2017). Higher number of known pancreatic cancer mutations highlighted by whole-transcripto- me and whole-exome sequencing predicts cli- nical outcome in early stage patients. MINERVA GASTROENTEROLOGICA E DIETOLOGICA, 63(Suppl. I N° 4), 21-21.
Elisa Grassi, Sandra Durante, Annalisa Astolfi, Giuseppe Tarantino, Valentina Indio, Eva Freier, Francesca Formica, Daria Filippini, Claudio Ricci, Ri...espandi
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/628730
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact